COURSE DIRECTOR
David Dingli, M.D., William Hogan, M.B., B.Ch., Luis Porrata, M.D. and Hassan Alkhateeb, M.D.

DESCRIPTION
This is a course intended for Mayo personnel only. It is a multidisciplinary Adult and Pediatric forum designed to enhance the practice and ensure excellence in all aspects of BMT. We discuss the onboarding of novel stem cell-based technologies such as gene therapy. In addition, we also discuss controversial cases as part of a patient selection process, presenting the data and literature in support and against transplantation for a specific circumstance. (Providers, APP, Nursing, Human cell Therapy, Transfusion medicine, Nutrition/ Dietetics, Pharmacy, Social work) 

TARGET AUDIENCE
Physicians, NP, PA, APP, Nursing, Human Cell Therapy, Transfusion Medicine, Nutrition/ Dietetics, Pharmacy, Social Work

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CREDIT STATEMENT(S)
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE SUMMARY
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies: 
David Dingli, M.D. - Consultant - Novartis Pharmaceuticals Corporation, 21GRAMS, Janssen Biotech, Inc., Alexion Pharmaceuticals, Inc., Advarra, Ossium Health, Inc., UCB Pharma GmbH, Immunome, Inc., Apellis Pharmaceuticals, Legend Biotech USA Inc, Genzyme Corporation, Second City Science, DAVA Oncology, LP, Argenx US Inc, Sanofi Genzyme, Curio Science LLC, Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp., Takeda Pharmaceuticals, Inc., Millenium International PPO.

All relevant financial relationships have been mitigated. 

 

No relevant financial relationship(s) with ineligible companies:
Hassan Alkhateeb, M.D.
William Hogan, M.B., B.Ch.
Luis Porrata, M.D.

Mikayla Baumgartner (Coordinator)
Michelle Ward (inactive 02/29/2024)

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.

 

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

 

TRANSCRIPT
Any credit or attendance awarded will appear on your Transcript.

QUESTIONS?
Contact Mikayla Baumgartner